BACKGROUND: The 2005 National Institutes of Health Consensus Development Conference on chronic graft-versus-host disease proposed major changes in the classification and grading of severity of chronic graft-versus-host disease. DESIGN AND METHODS: We aimed to study the association of the proposed chronic graft-versus-host disease classification and global severity with transplantation outcomes among a consecutive series of patients who received pharmacokinetically-targeted doses of intravenous busulfan and fludarabine conditioning followed by transplantation of allogeneic peripheral blood stem cells. RESULTS: From a total cohort (n = 242) of patients surviving more than 100 days after hematopoietic stem cell transplantation, 181 (75% of those at risk) had some manifestations of graft-versus-host disease after day 100. Of these, at onset 13 (7%) had late acute graft-versus-host disease, 62 (34%) had classic chronic graft-versus-host disease, and 106 (59%) had the overlap subtype of chronic graft-versus-host disease. The global severity of the chronic graft-versus-host disease was mild in 25% of cases, moderate in 46%, and severe in 29%. Multivariable modeling demonstrated the independent association of global severity of chronic graft-versus-host disease with overall survival (moderate/severe versus mild; HR 2.9, 95% CI 1.8-4.7, P < 0.0001) and non-relapse mortality (moderate versus mild; HR 3.86, 95% CI 1.17-12.73, P = 0.03, and severe versus mild (HR 10.06, 95% CI 3.07-32.97, P < 0.001). The type of onset of progressive chronic graft-versus-host disease and the platelet count at the time of diagnosis of the disease were significantly associated with overall survival. The occurrence and severity of chronic graft-versus-host disease was also significantly associated with primary disease relapse. CONCLUSIONS: Patients with moderate to severe chronic graft-versus-host disease, as determined by National Institutes of Health Consensus criteria, have an inferior overall survival and worse non-relapse mortality. Clinical and research advances are needed to improve the outcomes of affected patients.
BACKGROUND: The 2005 National Institutes of Health Consensus Development Conference on chronic graft-versus-host disease proposed major changes in the classification and grading of severity of chronic graft-versus-host disease. DESIGN AND METHODS: We aimed to study the association of the proposed chronic graft-versus-host disease classification and global severity with transplantation outcomes among a consecutive series of patients who received pharmacokinetically-targeted doses of intravenous busulfan and fludarabine conditioning followed by transplantation of allogeneic peripheral blood stem cells. RESULTS: From a total cohort (n = 242) of patients surviving more than 100 days after hematopoietic stem cell transplantation, 181 (75% of those at risk) had some manifestations of graft-versus-host disease after day 100. Of these, at onset 13 (7%) had late acute graft-versus-host disease, 62 (34%) had classic chronic graft-versus-host disease, and 106 (59%) had the overlap subtype of chronic graft-versus-host disease. The global severity of the chronic graft-versus-host disease was mild in 25% of cases, moderate in 46%, and severe in 29%. Multivariable modeling demonstrated the independent association of global severity of chronic graft-versus-host disease with overall survival (moderate/severe versus mild; HR 2.9, 95% CI 1.8-4.7, P < 0.0001) and non-relapse mortality (moderate versus mild; HR 3.86, 95% CI 1.17-12.73, P = 0.03, and severe versus mild (HR 10.06, 95% CI 3.07-32.97, P < 0.001). The type of onset of progressive chronic graft-versus-host disease and the platelet count at the time of diagnosis of the disease were significantly associated with overall survival. The occurrence and severity of chronic graft-versus-host disease was also significantly associated with primary disease relapse. CONCLUSIONS:Patients with moderate to severe chronic graft-versus-host disease, as determined by National Institutes of Health Consensus criteria, have an inferior overall survival and worse non-relapse mortality. Clinical and research advances are needed to improve the outcomes of affected patients.
Authors: Gorgun Akpek; Stephanie J Lee; Mary E Flowers; Steven Z Pavletic; Mukta Arora; Shing Lee; Steven Piantadosi; Katherine A Guthrie; James C Lynch; Alessandra Takatu; Mary M Horowitz; Joseph H Antin; Daniel J Weisdorf; Paul J Martin; Georgia B Vogelsang Journal: Blood Date: 2003-04-24 Impact factor: 22.113
Authors: Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer Journal: Blood Date: 2005-06-30 Impact factor: 22.113
Authors: Steven Z Pavletic; Lynette M Smith; Michael R Bishop; James C Lynch; Stefano R Tarantolo; Julie M Vose; Philip J Bierman; Abdul Hadi; James O Armitage; Anne Kessinger Journal: Am J Hematol Date: 2005-04 Impact factor: 10.047
Authors: Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2005-12 Impact factor: 5.742
Authors: J R Wingard; S Piantadosi; G B Vogelsang; E R Farmer; D A Jabs; L S Levin; W E Beschorner; R A Cahill; D F Miller; D Harrison Journal: Blood Date: 1989-09 Impact factor: 22.113
Authors: Betty L Stewart; Barry Storer; Jan Storek; H Joachim Deeg; Rainer Storb; John A Hansen; Frederick R Appelbaum; Paul A Carpenter; Jean E Sanders; Hans-Peter Kiem; Richard A Nash; Effie W Petersdorf; Carina Moravec; A James Morton; Claudio Anasetti; Mary E D Flowers; Paul J Martin Journal: Blood Date: 2004-08-03 Impact factor: 22.113
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: Joseph Pidala; Jongphil Kim; Melissa Alsina; Ernesto Ayala; Brian C Betts; Hugo F Fernandez; Teresa Field; Heather Jim; Mohamed A Kharfan-Dabaja; Frederick L Locke; Asmita Mishra; Taiga Nishihori; Leonel Ochoa-Bayona; Lia Perez; Marcie Riches; Claudio Anasetti Journal: Haematologica Date: 2015-04-03 Impact factor: 9.941
Authors: Sarah Nikiforow; Haesook T Kim; Bhavjot Bindra; Sean McDonough; Brett Glotzbecker; Philippe Armand; John Koreth; Vincent T Ho; Edwin P Alyea; Bruce R Blazar; Jerome Ritz; Robert J Soiffer; Joseph H Antin; Corey S Cutler Journal: Biol Blood Marrow Transplant Date: 2013-02-14 Impact factor: 5.742
Authors: Betty K Hamilton; Lisa Rybicki; Sally Arai; Mukta Arora; Corey S Cutler; Mary E D Flowers; Madan Jagasia; Paul J Martin; Jeanne Palmer; Joseph Pidala; Navneet S Majhail; Stephanie J Lee; Nandita Khera Journal: Biol Blood Marrow Transplant Date: 2017-10-12 Impact factor: 5.742
Authors: Shernan G Holtan; Nandita Khera; John E Levine; Xiaoyu Chai; Barry Storer; Hien D Liu; Yoshihiro Inamoto; George L Chen; Sebastian Mayer; Mukta Arora; Jeanne Palmer; Mary E D Flowers; Corey S Cutler; Alexander Lukez; Sally Arai; Aleksandr Lazaryan; Laura F Newell; Christa Krupski; Madan H Jagasia; Iskra Pusic; William Wood; Anne S Renteria; Gregory Yanik; William J Hogan; Elizabeth Hexner; Francis Ayuk; Ernst Holler; Phandee Watanaboonyongcharoen; Yvonne A Efebera; James L M Ferrara; Angela Panoskaltsis-Mortari; Daniel Weisdorf; Stephanie J Lee; Joseph Pidala Journal: Blood Date: 2016-09-13 Impact factor: 22.113
Authors: G Lia; L Brunello; S Bruno; A Carpanetto; P Omedè; M Festuccia; L Tosti; E Maffini; L Giaccone; M Arpinati; G Ciccone; M Boccadoro; A Evangelista; G Camussi; B Bruno Journal: Leukemia Date: 2017-08-30 Impact factor: 11.528
Authors: Corey Cutler; Haesook T Kim; Bhavjot Bindra; Stefanie Sarantopoulos; Vincent T Ho; Yi-Bin Chen; Jacalyn Rosenblatt; Sean McDonough; Phandee Watanaboonyongcharoen; Philippe Armand; John Koreth; Brett Glotzbecker; Edwin Alyea; Bruce R Blazar; Robert J Soiffer; Jerome Ritz; Joseph H Antin Journal: Blood Date: 2013-07-16 Impact factor: 22.113